nifedipine has been researched along with simvastatin in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.00) | 18.2507 |
| 2000's | 7 (28.00) | 29.6817 |
| 2010's | 16 (64.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Bharate, SS; Vishwakarma, RA | 1 |
| Beaumont, K; Di, L; Maurer, TS; Smith, DA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Eda, T; Hidaka, Y; Kamei, T; Yonemoto, M | 1 |
| Cesari, M; Pessina, AC | 1 |
| Chiou, SY; Lai, GW; Lin, G; Lin, LY | 1 |
| Ito, S; Ito, Y; Kondo, M; Kume, H; Naruse, K; Oguma, T; Shimokata, K; Suki, B | 1 |
| Chen, XN; Fan, M; Feng, Z; Han, JY; Xu, J; Yang, Z | 1 |
| Hayashi, M; Shou, M; Skiles, GL; Xu, Y; Zhou, Y | 1 |
| Damen, CW; González, O; Hankemeier, T; van der Kloet, FM; van Vliet, M; Vreeken, RJ | 1 |
| D'Angelo, A; Derosa, G; Maffioli, P; Mugellini, A; Pesce, RM | 1 |
| Cruz-Angeles, J; Martínez, LM; Martínez-Jiménez, C; Videa, M | 1 |
| Chen, J; Cheng, H; Cheng, J; Ke, Y; Li, H; Li, J; Li, X; Wang, Z; Yuan, D | 1 |
2 review(s) available for nifedipine and simvastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Combined antihypertensive and lipid-lowering treatment.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Arteriosclerosis; Cardiovascular Diseases; Comorbidity; Drug Therapy, Combination; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Nifedipine; Pyridines; Simvastatin | 2004 |
1 trial(s) available for nifedipine and simvastatin
| Article | Year |
|---|---|
Perindopril and barnidipine alone or combined with simvastatin on hepatic steatosis and inflammatory parameters in hypertensive patients.
Topics: Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Hypolipidemic Agents; Male; Nifedipine; Non-alcoholic Fatty Liver Disease; Obesity; Perindopril; Simvastatin | 2015 |
22 other study(ies) available for nifedipine and simvastatin
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Thermodynamic equilibrium solubility measurements in simulated fluids by 96-well plate method in early drug discovery.
Topics: Drug Discovery; Pharmaceutical Preparations; Solubility; Thermodynamics | 2015 |
Volume of Distribution in Drug Design.
Topics: Drug Design; Half-Life; Pharmacokinetics | 2015 |
Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733).
Topics: Animals; Anticholesteremic Agents; Aorta, Thoracic; Benzylamines; Cell Movement; Cells, Cultured; Dose-Response Relationship, Drug; Fibrinogen; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Lovastatin; Mevalonic Acid; Muscle, Smooth, Vascular; Nifedipine; Platelet-Derived Growth Factor; Pravastatin; Simvastatin; Sterols; Swine; Thiophenes | 1992 |
Kinetics and mechanisms of cholesterol esterase inhibition by cardiovascular drugs in vitro.
Topics: Amlodipine; Cardiovascular Agents; Enzyme Inhibitors; Hydralazine; Kinetics; Nifedipine; Octoxynol; Simvastatin; Sterol Esterase; Taurocholic Acid | 2006 |
Roles of stretch-activated cation channel and Rho-kinase in the spontaneous contraction of airway smooth muscle.
Topics: Amides; Animals; Calcium; Calcium Channel Blockers; Calcium Channels, L-Type; Cations; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Gadolinium; Guinea Pigs; Imidazoles; In Vitro Techniques; Indomethacin; Intracellular Signaling Peptides and Proteins; Ion Channels; Male; Methacholine Chloride; Muscle Contraction; Muscle, Smooth; Nifedipine; Nitrobenzenes; Protein Serine-Threonine Kinases; Pyrazoles; Pyridines; rho-Associated Kinases; Simvastatin; Stress, Mechanical; Sulfonamides; Trachea | 2006 |
Simvastatin combined with nifedipine enhances endothelial cell protection by inhibiting ROS generation and activating Akt phosphorylation.
Topics: Blotting, Western; Calcium Channel Blockers; Drug Interactions; Endothelial Cells; Humans; Hydrogen Peroxide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Nifedipine; Nitric Oxide Synthase Type III; Phosphorylation; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Simvastatin; Umbilical Veins; Up-Regulation | 2010 |
Simulation of clinical drug-drug interactions from hepatocyte CYP3A4 induction data and its potential utility in trial designs.
Topics: Area Under Curve; Carbamazepine; Cytochrome P-450 CYP3A; Drug Interactions; Enzyme Induction; Hepatocytes; Humans; Midazolam; Nifedipine; Phenobarbital; Rifampin; Simvastatin; Substrate Specificity | 2011 |
Matrix Effect Compensation in Small-Molecule Profiling for an LC-TOF Platform Using Multicomponent Postcolumn Infusion.
Topics: Acetaminophen; Benzimidazoles; Benzoates; Biphenyl Compounds; Chromatography, High Pressure Liquid; Clomipramine; Dihydropyridines; Enkephalin, Leucine; Humans; Mass Spectrometry; Nifedipine; Pharmaceutical Preparations; Simvastatin; Telmisartan; Tetrazoles; Time Factors | 2015 |
Co-Amorphous Simvastatin-Nifedipine with Enhanced Solubility for Possible Use in Combination Therapy of Hypertension and Hypercholesterolemia.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Calorimetry, Differential Scanning; Drug Combinations; Drug Compounding; Drug Liberation; Drug Stability; Hypercholesterolemia; Hypertension; Molecular Structure; Nifedipine; Simvastatin; Solubility; Spectroscopy, Fourier Transform Infrared; X-Ray Diffraction | 2018 |
Co-amorphous systems using epigallocatechin-3-gallate as a co-former: Stability, in vitro dissolution, in vivo bioavailability and underlying molecular mechanisms.
Topics: Animals; Biological Availability; Calorimetry, Differential Scanning; Catechin; Drug Stability; Nifedipine; Rats; Simvastatin; Solubility; Spectroscopy, Fourier Transform Infrared; X-Ray Diffraction | 2022 |